Lutetium Lu 177 vipivotide tetraxetan: A literature review.
Lutetium Lu 177 vipivotide tetraxetan shows promise for treating mCRPC, but ongoing studies are needed to clarify its effectiveness in earlier stages of the disease.
Where it sits
this study against the rest of the vipivotide corpusSummary and findings
This literature review evaluates the pharmacology, pharmacokinetics, and safety of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). It reports on findings from two phase III clinical trials where the treatment was administered at a dose of 7.4 GBq intravenously every 6 weeks for up to 6 doses. The review indicates that the treatment is generally well tolerated with specific adverse effects noted.
Abstract
To review pharmacology, pharmacokinetics, therapeutic use, product safety/description and perspectives on use of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). <b>Data sources:</b> A literature search was conducted using PubMed/Dynamed (October 2013-May 2025), limited to English language, humans, clinical trials, case reports, and guidelines. <b>Data summary:</b> Lutetium Lu 177 vipivotide tetraxetan is comprised of the beta-emitting radioisotope lutetium Lu-177 linked to a peptide, vipivotide tetraxetan, which binds to cells expressing prostate-specific membrane antigen (PSMA), resulting in cell death from the radiation. Kidney excretion may result in increased renal toxicity in patients with reduced renal function. Based on 2 phase III clinical trials, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq administered intravenously every 6 weeks for up to 6 doses is effective in patients with mCRPC and PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor and docetaxel therapy or an androgen receptor pathway inhibitor alone, by significantly improving radiographic progression-free survival. It is generally well tolerated, with asthenia/fatigue, dry mouth, mild nausea and low-grade anemia most commonly occurring. Severe adverse drug reactions are uncommon. It should only be administered by trained personnel in a designated clinical setting with existing radiation safety protocols. Patients must limit close contact, use precautions with using the bathroom and other daily activities in days following treatment. Patient education is necessary to ensure safe daily practices. Several ongoing trials are evaluating lutetium Lu 177 vipivotide tetraxetan in combination with other anticancer agents for treatment of mCRPC, using different dosing strategies, or in other settings (metastatic castration-sensitive prostate cancer and early-stage prostate cancer). <b>Conclusion:</b> Lutetium Lu 177 vipivotide tetraxetan is an effective and well tolerated treatment for patients with mCRPC, PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor ± docetaxel. Ongoing studies evaluating its use in earlier disease stages and with different dosing strategies, will better define the role of this therapy in the treatment of prostate cancer.
Background
The paper addresses the clinical question of the efficacy and safety of lutetium Lu 177 vipivotide tetraxetan for treating metastatic castration-resistant prostate cancer (mCRPC). Prior knowledge indicated that this treatment targets cells expressing prostate-specific membrane antigen (PSMA) and utilizes a beta-emitting radioisotope. This review is significant as it compiles findings from multiple studies to inform clinical practice regarding this therapy.
Methods
A literature search was conducted using PubMed/Dynamed from October 2013 to May 2025, focusing on English-language studies involving humans, clinical trials, case reports, and guidelines. The review summarizes data from two phase III clinical trials assessing the treatment's effectiveness and safety profile.
Results
The review indicates that lutetium Lu 177 vipivotide tetraxetan significantly improves radiographic progression-free survival in patients with mCRPC and PSMA-positive metastases. Specific numeric outcomes related to survival rates or statistical significance were not detailed in the abstract.
Interpretation
While the findings suggest that lutetium Lu 177 vipivotide tetraxetan is effective, the lack of detailed statistical results limits the ability to assess the clinical significance of the observed effects. The review highlights the need for ongoing studies to further evaluate the treatment's role in earlier disease stages and with varying dosing strategies. Confounding factors include the reliance on existing literature without original data analysis.
Key findings
- 7.4 GBq administered intravenously every 6 weeks for up to 6 doses.
- Significantly improving radiographic progression-free survival in patients with mCRPC and PSMA-positive metastases.
- Most common adverse effects include asthenia/fatigue, dry mouth, mild nausea, and low-grade anemia.
- Severe adverse drug reactions are uncommon.
Limitations
- Not reported in abstract.
- No specific numeric outcomes or detailed statistical analyses provided.
- Review based on existing literature without original data.